#BREZTRI

[dgf2099]

The Driver Suit Blog-Paint Scheme Tracker-April 10, 2024

By David G. Firestone TRACKHOUSE RACING #1 Ross Chastain #1 Moose Fraternity Chevy Camaro–New scheme for 2024, red roof added. A Ross Chastain #1 Busch Light Chevy Camaro–New scheme for 2024, sides cleaned up. A Ross Chastain #1 Busch Light Fishing Chevy Camaro-New sponsor for 2024, white with fishing motif. D- Ross Chastain #1 Worldwide Express Chevy Camaro–No change. F TEAM PENSKE #2 Austin…

[nascarwallpapers]

2023 NASCAR Cup Series: Austin Dillon, #3 BREZTRI Chevrolet, Richard Childress Racing. Download full resolution & extras on Patreon.

[reasonsforhope]

Less than three months after U.S. Senator Tammy Baldwin and her colleagues launched an investigation into the four major American manufacturers of inhalers, three of the companies have relented, making commitments to cap costs for their inhalers at $35 for patients who now pay much more.

25 million Americans have asthma and 16 million Americans have chronic obstructive pulmonary disease (COPD), meaning over 40 million Americans rely on inhalers to breathe.

Inhalers have been available since the 1950s, and most of the drugs they use have been on the market for more than 25 years.

According to a statement from the Wisconsin Senator’s office, inhaler manufacturers sell the exact same products at a much lower costs in other countries. One of AstraZeneca’s inhalers, Breztri Aerosphere, costs $645 in the U.S.—but just $49 in the UK. Inhalers made by Boehringer Ingelheim, GlaxoSmithKline, and Teva have similar disparities.

Baldwin and her Democratic colleagues—New Mexico Sen. Ben Ray Luján, Massachusetts Sen. Ed Markey, and Vermont Sen. Bernie Sanders—pressured the companies to lower their prices by writing letters to GSK, Boehringer Ingelheim, Teva, and AstraZeneca requesting a variety of documents that show why such higher prices are charged in America compared to Europe.

As a ranking member of the Senate Committee on Health, Education, Labor, and Pensions, Baldwin recently announced that as a result of the letters they had secured commitments from three of the four to lower the out-of-pocket costs of inhalers to a fixed $35.00 rate.

“For the millions of Americans who rely on inhalers to breathe, this news is a major step in the right direction as we work to lower costs and hold big drug companies accountable,” said Senator Baldwin.

A full list of the inhalers and associated drugs can be viewed here.

It’s the second time in the last year that pharmaceutical companies were forced to provide reasonable prices—after the cost of insulin was similarly capped successfully at $35 per month thanks to Congressional actions led by the White House.

-via Good News Network, March 25, 2024

[good-morning-czernobog]

We have a transcription system for voicemails at my work. Someone was calling about an inhaler called Breztri. Let me tell you, the laugh that came out of me when I saw the system had transcribed it as 'breast tree' was simply inhuman.

[38mag]

AstraZeneca 推出三联疗法 Breztri Aerosphere® 为治疗慢性阻塞性肺病(COPD) 迈进一大步

慢性阻塞性肺病（COPD）是一种严重的肺部疾病，会使得病患气道变窄、阻塞和发炎并导致呼吸困难。慢性阻塞性肺病的症状（COPD）： 呼吸急促 喘鸣 胸闷 咳嗽 疲劳 粘液(痰) 频繁呼吸道感染 原因： 吸烟 二手烟 烟雾、化学物质 粉尘 儿童呼吸道感染的基因遗传和个人病史 当症状恶化时，慢COPD可能会突然发作。这会导致患者的生活质��日渐变得很糟糕，，严重时甚至需要住院治疗。因此，有效管理COPD发作，对于避免患者肺部出现潜在性长期损害，以及预防相关的心血管病至关重要。 AstraZeneca(阿斯利康)是一家全球性生物制药公司，其马来西亚子公司成立于1981年。它是其中一家专注于呼吸护理领域领先研发的制药公司。该公司组织了一场汇集医疗护理专业人员的慢性阻塞性肺病(Chronic Obstructive Pulmonary…

[atsa-star-wars]

I'm doing kind of the opposite with my fics. I'm a pharmacy tech and I work in a large central fill facility, so I see a bunch of nifty-sounding brand names, and I've decided to sprinkle them into my (currently Star Wars) fic. Cresemba is a planet, Stelara House makes kink paraphernalia, Master Kerendia the retired Jedi healer (prequel era).

Zetonna, Wixela, Stiolto, Rinvoq, Breztri, Orilissa, Steglujan...there's so much to work with.

so we all know as fantasy writers that you need to google your made up words before you start using them.

i'm now extending this rule to pharmaceutical companies:

[inhalersonline-com]

Breztri Aerosphere is a doctor prescribed drug utilized as upkeep therapy for Chronic obstructive aspiratory infection (COPD) which incorporates ongoing bronchitis and emphysema.

[quadrepedd]

COMPUTER NEEDS Sustenance

sustenance for computer is needed, I ahave asthma!!!!! GIVE ME MY BREZTRI IM DYING. MOM STOP BEATING ME UP IVE BEEN A GOOD BOY I SWEAR, I SWEAR STOP BEATING TME UP MOM PLEASE

[atsa-star-wars]

Here are a few Star Wars-sounding drug names from the pharmacy, if you're interested:

Adcirca, Prezistra, Azasan, Delstrigo, Beyaz, Elmiron, Evista, Bevespi, Zetonna, Wixela, Stiolto, Dulera, Rinvoq, Breztri, Anoro, Aurovela

Want to help rename my OC?

So, I apparently named an original character in my Star Wars fanfic with an archaic female insult. (Once it was pointed out, I suspected I used to know that, but have long since forgotten about the historical (or any) use of the word). Oops.

I need to replace the name in . . . 2 separate fics. (No, nobody mentioned it in the comments the first time when she was just a name and a mention so I blithely had her make a full appearance in a different fic.

Suggestions welcome.

The offensive name: Quim.

I don't want to just change it to Quin, because Quinlan Vos (canon character) sometimes goes by Quin. I also have another character in a different fic called Quirret, so maybe I should just go in a totally different direction? Another letter?

The character is a former padawan of Yoda's, several before Dooku, though he knows her in her elder years. She is avian, she has feathers (which periodically moult) and while she can't actually fly, she can use her feathers to glide gracefully.

Any ideas on how we can rename her? Quail, while a bird, has a meaning as a verb which is not suitable for her character. Also, her plumage is bright in color.

[leanpick]

Breztri Aerosphere to be listed on PBS from November 1 to treat chronic obstructive pulmonary disease

Breztri Aerosphere to be listed on PBS from November 1 to treat chronic obstructive pulmonary disease

Australians living with chronic obstructive pulmonary disease will have access to a new treatment from Monday.

[dgf2099]

The Driver Suit Blog-Paint Scheme Tracker-April 3, 2024

By David G. Firestone TRACKHOUSE RACING #1 Ross Chastain #1 Moose Fraternity Chevy Camaro–New scheme for 2024, red roof added. A Ross Chastain #1 Busch Light Chevy Camaro–New scheme for 2024, sides cleaned up. A Ross Chastain #1 Busch Light Fishing Chevy Camaro-New sponsor for 2024, white with fishing motif. D- Ross Chastain #1 Worldwide Express Chevy Camaro–No change. F TEAM PENSKE #2 Austin…

[letsjanukhan]

Medication for debilitating lung condition added to PBS

Medication for debilitating lung condition added to PBS

Tens of thousands of Australians with a debilitating lung condition are expected to benefit from a medication that will be more affordable from Monday. The inhaler called Breztri Aerosphere will be added to the Pharmaceutical Benefits Scheme reducing the cost from $1000 a year to $41.30 per script or $6.60 for concession cardholders. The inhaler contains three different medications to reduce…

[cutipop1]

Breztri Aerosphere Commercial (2021)

[csdataabase]

Ztri Customer Service

If you are looking for ztri customer service, simply check out our links below : 1. BREZTRI AEROSPHERE™ (budesonide 160 mcg … https://www.breztri.com/#:~:text=The%20Information%20Center%20at%20AstraZeneca,8%20PM%20ET%2C%20excluding%20holidays.&text=AstraZeneca%20is%20committed%20to%20providing,them%20during%20these%20uncertain%20times. 2. Tri-Point Substation Services |…

[pharmaphorumuk]

GSK hits trouble with Trelegy as EU regulators block asthma indication

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the fortunes of its respiratory diseases franchise.

The company had been propped for years thanks to its ageing asthma and COPD inhaler Advair, which finally succumbed to generic competition in the US in 2019, years after its patent expired.

GSK has no plans to appeal and has no further studies planned for European approval, after regulators from the CHMP scientific committee gave a negative opinion on the triple therapy.

The UK pharma had applied for a label extension for the drug, which is already approved in chronic obstructive pulmonary disease (COPD) since 2017, to cover patients with asthma.

But the CHMP said that while trial evidence showed Trelegy improved lung function, it could not approve the drug because of the lack of evidence to show it cut the risk of exacerbations.

GSK’s problems with Trelegy, developed in partnership with Innoviva, stem from the phase 3 CAPTAIN study, which reported findings in May 2019.

This showed a statistically significant improvement in lung function compared with GSK’s double therapy Relvar/Breo (fluticasone furoate+umeclidinium), meeting its primary endpoint.

But it fell short on the secondary endpoint of an improvement of a reduction in the annual rate of moderate to severe exacerabations.

The trial showed a 13% reduction in exacerbations but this figure was not statistically significant.

The CHMP’s decision runs counter to that of the FDA, which okayed Trelegy in the asthma indication in September despite the issue with the data from CAPTAIN.

It’s also a bonus for AstraZeneca, which almost simultaneously reported phase 3 trial findings showing its injected drug tezepelumab can cut exacerbations in severe asthma.

AZ is also developing a rival triple therapy inhaler, Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), which is already approved in the US in COPD and is in late-stage development in asthma.

A GSK spokesperson said: “We have a strong track record of bringing new treatment options to asthma patients in Europe and so while we are disappointed that these patients will not have access to Trelegy Ellipta for asthma, we remain committed to supporting them with our existing portfolio of medicines and investigating further innovative treatment options for asthma.”

“Trelegy Ellipta is already approved in four markets to date including the US and Japan for the treatment of asthma. These approvals were based on robust data which showed Trelegy Ellipta improved lung function and symptom control in adult asthma patients.”

The post GSK hits trouble with Trelegy as EU regulators block asthma indication appeared first on .

from https://pharmaphorum.com/news/gsk-hits-trouble-with-trelegy-as-eu-regulators-block-asthma-indication/

[mhealthyliving]

Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD).